Latest Industry Insights

Early stage biotech company Aqualung Therapeutics is currently developing a therapeutic monoclonal antibody – ALT-100 – for the treatment of unchecked inflammation. COVID-19 can cause severe pneumonia and respiratory failure. There is therefore a potential option to treat patients diagnosed with COVID-19 with ALT-100. Technology Networks recently spoke with Joe Garcia, MD, Founder and Chief Executive Officer of Aqualung Therapeutics to learn more.

CEL-SCI Corporation recently announced that it is utilizing LEAPS peptide technology in efforts to develop an immunotherapy against the novel coronavirus caused by SARS-CoV-2. Technology Networks, spoke with Daniel Zimmerman, Ph.D. Senior VP of Research, Cellular Immunology at CEL-SCI Corporation, to learn more about the LEAPS technology.

Cancer immunotherapies and viral vaccines that are nucleic acid-based can be challenging to formulate and require highly specific delivery systems. Commonly adopted delivery systems, such as lipid nanoparticles and viral vectors, can have limitations, therefore alternative approaches are being developed. Technology Networks recently spoke with Nigel Theobald, CEO and Founder of N4 Pharma, to learn more about nanoparticle drug delivery, the Nuvec® platform and its progress towards clinical trials.

Technology Networks recently spoke with Dr Jacques Ravel (Chief Scientist of LUCA Biologics) and Luba Greenwood (CEO of LUCA Biologics) to learn more about what the vaginal microbiome is, how it can contribute to human pathology and the development of novel therapeutics in this space that are approaching clinical trials.

We recently had the pleasure of speaking with William Levine, D.D.S., CannRx Founder and Chief Scientific Officer. Levine discusses CannRx’s mission to develop transformative, scientifically based, proprietary cannabis technologies, highlights some of the medical applications of cannabis-derived products, and explains why it is so important to analyze the various active compounds in cannabis.

With the number of new cancer cases worldwide per year predicted to rise to 23.6 million by 2030, it seems as pertinent as ever that the disease is stopped early in its tracks. We spoke with Mike Fisher, Ph.D., Commercial Director of Oncimmune, to find out more about a trial utilizing a simple blood test for early detection of lung cancer.

What barriers still exist to the full implementation of next-generation sequencing (NGS) in the diagnostics space, and how can we remove them? Technology Networks recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific, to learn more.

Technology Networks recently had the pleasure of speaking with Bruce Steel, CEO Equillium, Inc. to learn more about how they are leveraging their comprehensive understanding of immunobiology to develop novel treatments for inflammatory and autoimmune disorders.

The pharmaceutical market is in a period of transition as the introduction of new biosimilars increases. Here, George I'ons, Owen Mumford Pharmaceutical Services, explores a lesser known but albeit important factor influencing the success of this transitional period is delivery device design of such drugs.

The study of brain tumors using real-time imaging of the brain in live disease models is critical for elucidating disease mechanisms and developing novel treatment strategies. Such research requires full characterization of healthy and disease phenotypes using a multi-omics analysis, as described in this blog.